- Home
- CFR vs ROIV Comparison
CFR vs ROIV Comparison
Compare CFR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- ROIV
- Stock Information
- Founded
- CFR 1868
- ROIV 2014
- Country
- CFR United States
- ROIV United Kingdom
- Employees
- CFR N/A
- ROIV N/A
- Industry
- CFR Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CFR Finance
- ROIV Health Care
- Exchange
- CFR Nasdaq
- ROIV Nasdaq
- Market Cap
- CFR 8.0B
- ROIV 8.6B
- IPO Year
- CFR N/A
- ROIV N/A
- Fundamental
- Price
- CFR $128.12
- ROIV $12.92
- Analyst Decision
- CFR Hold
- ROIV Strong Buy
- Analyst Count
- CFR 15
- ROIV 4
- Target Price
- CFR $136.40
- ROIV $15.50
- AVG Volume (30 Days)
- CFR 448.4K
- ROIV 5.2M
- Earning Date
- CFR 10-30-2025
- ROIV 08-11-2025
- Dividend Yield
- CFR 3.11%
- ROIV N/A
- EPS Growth
- CFR 13.33
- ROIV N/A
- EPS
- CFR 9.29
- ROIV N/A
- Revenue
- CFR $2,079,741,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CFR $13.32
- ROIV N/A
- Revenue Next Year
- CFR $4.15
- ROIV $281.14
- P/E Ratio
- CFR $13.84
- ROIV N/A
- Revenue Growth
- CFR 6.87
- ROIV N/A
- 52 Week Low
- CFR $100.31
- ROIV $8.73
- 52 Week High
- CFR $147.64
- ROIV $13.08
- Technical
- Relative Strength Index (RSI)
- CFR 47.70
- ROIV 73.31
- Support Level
- CFR $127.14
- ROIV $11.85
- Resistance Level
- CFR $130.46
- ROIV $13.08
- Average True Range (ATR)
- CFR 2.31
- ROIV 0.31
- MACD
- CFR 0.27
- ROIV 0.10
- Stochastic Oscillator
- CFR 48.36
- ROIV 89.61
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.